or Try an Advanced Search...

    Halozyme Stocks List

    Symbol Grade Name % Change
    HALO F Halozyme Therapeutics, Inc. 7.22
    NXTC F NextCure, Inc. -7.75
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Solid Tumors Antibodies Biotechnology Cancer Cancer Treatment Clinical Development Clinical Medicine Clinical Trial Product Diabetes Diabetes Mellitus Enzymes Hoffmann La Roche Hyaluronidase Immune Related Diseases Immunotherapy Insulin Intrexon Life Sciences Medicine

    Related ETFs - A few ETFs which own one or more of the above listed Halozyme stocks.

    Symbol Grade Name Weight
    FBT C First Trust Amex Biotech Index Fund 3.44
    CSMD A Congress SMid Growth ETF 2.45
    PBE C PowerShares Dynamic Biotech & Genome 2.42
    FFND A The Future Fund Active ETF 1.44
    BBP C BioShares Biotechnology Products Fund 1.38
    View all Halozyme ETFs...
    Compare ETFs
    Compare CSMD to BBP Compare PBE to BBP Compare PBE to FFND

        Halozyme Stocks Recent News

        Date Stock Title
        Nov 22 HALO Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
        Nov 22 HALO Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why
        Nov 22 HALO Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
        Nov 22 HALO Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal
        Nov 22 HALO Halozyme withdraws $2.1 billion buyout offer for Evotec
        Nov 22 HALO Halozyme gains after withdrawing Evotec bid
        Nov 22 HALO Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
        Nov 22 HALO Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
        Nov 20 HALO Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
        Nov 19 HALO 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
        Nov 19 HALO HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
        Nov 19 HALO Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?
        Nov 19 HALO Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
        Nov 19 NXTC Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
        Nov 18 HALO Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
        Nov 17 HALO Halozyme plans to finance $2.1B takeover of Evotech in cash: report
        Nov 17 HALO Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Solid Tumors Antibodies Biotechnology Cancer Cancer Treatment Clinical Development Clinical Medicine Clinical Trial Product Diabetes Diabetes Mellitus Enzymes Hoffmann La Roche Hyaluronidase Immune Related Diseases Immunotherapy Insulin Intrexon Life Sciences Medicine
        Halozyme

        Halozyme Therapeutics is a U.S. biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.
        The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

        More about Halozyme
        Browse All Tags